Last update 14 May 2025

Zeushield Cytotoxic T Lymphocytes(Hunan Zhaotai Yongren Medical)

Overview

Basic Info

Drug Type
CAR-T
Synonyms
Z-CTLs
Target
CD80 x CD86 x PDL1
Action
inhibitors
Mechanism
CD80 inhibitors(Cluster of differentiation 80 inhibitors), CD86 inhibitors(Cluster of differentiation 86 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication-
Inactive Indication
Non-Small Cell Lung CancerRecurrent Non-Small Cell Lung Cancer
Originator Organization
Hunan Zhaotai Yongren Medical Innovation Co., Ltd.
Active Organization-
Inactive Organization
Hunan Zhaotai Yongren Medical Innovation Co., Ltd.Xiangya Hospital Central South UniversityXiangya Hospital Central South University
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Zeushield Cytotoxic T Lymphocytes(Hunan Zhaotai Yongren Medical)
NCT03060343
/ Unknown statusEarly Phase 1IIT
Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting PD-L1 and CD80/CD86 (Zeushield Cytotoxic T Lymphocytes) for the Treatment of Recurrent or Refractory Non Small Cell Lung Cancer
100 Clinical Results associated with Zeushield Cytotoxic T Lymphocytes(Hunan Zhaotai Yongren Medical)
Login to view more data
100 Translational Medicine associated with Zeushield Cytotoxic T Lymphocytes(Hunan Zhaotai Yongren Medical)
Login to view more data
100 Patents (Medical) associated with Zeushield Cytotoxic T Lymphocytes(Hunan Zhaotai Yongren Medical)
Login to view more data
100 Deals associated with Zeushield Cytotoxic T Lymphocytes(Hunan Zhaotai Yongren Medical)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Non-Small Cell Lung CancerPhase 1
China
Hunan Zhaotai Yongren Medical Innovation Co., Ltd.
28 Nov 2016
Recurrent Non-Small Cell Lung CancerPhase 1
China
Xiangya Hospital Central South UniversityXiangya Hospital Central South University
28 Nov 2016
Non-Small Cell Lung CancerPhase 1
China
Hunan Zhaotai Yongren Medical Innovation Co., Ltd.
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free